Microarrayed compound screening format (µARCS) is a novel high-throughput screening technology that uses agarose matrices to integrate various biochemical or biological reagents in the assay. To evaluate the feasibility of using the µARCS technology for nucleic acid polymerization assays, the authors developed HIV reverse transcription (RT) and E1-dependent human papillomavirus (HPV) replication assays in this format. HIV RT is an RNA-dependent DNA polymerase, whereas HPV E1 is a DNA helicase. To ensure the efficient capture of the nucleic acid polymerization reaction and to minimize the nonspecific binding, the authors used a SAM 2® biotin capture membrane in the assay. In both studies, the nucleic acid substrate was biotinylated on one end and was bound to the SAM 2® membrane. A low melting-point agarose gel containing the rest of the reaction components was first placed on a polystyrene sheet spotted with compounds to allow passive diffusion of the compounds into the gel. The gel was removed from the compound sheet and applied to the SAM 2® membrane with the immobilized nucleic acid template to initiate the polymerization. After the incubation, the membrane was washed with a high-salt buffer and exposed for imaging. Potential inhibitors can be seen as white spots on a dark background. The sensitivity for the known inhibitors appears to be comparable in µARCS as in a traditional 96-well plate assay. The methodology described in this paper further expands the applications of µARCS technology. (Journal of Biomolecular Screening 2003:273-282) Xuei et al. 278 www.sbsonline.org Journal of Biomolecular Screening 8(3); 2003 FIG. 4. Effect of reduction of biotin-primer/RNA and reverse transcriptase concentrations on the detection response to efavirenz. An RT variant was used to optimize the detection response of the assay to efavirenz. Efavirenz was spotted in amounts ranging from 0.15 to 5 pmol. (A) 25 nM of the biotinprimer/RNA substrate and 25 nM of the RT variant were used to make the binding mixture solution. (B) One-half of the concentrations of the biotinprimer/RNA substrate and the RT variant of A were applied to the mixture solution.
INTRODUCTION
S EVERAL METHODOLOGIES HAVE BEEN DEVELOPED and used in high-throughput screening (HTS) to find inhibitors for nucleic acid polymerization targets in 96-well and the higher density microplate format. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] However, these methods generally demand large amounts of enzyme/substrate reagents, as well as high quantities of compounds, and require expensive automated robotic equipment to achieve reasonable throughput to screen a library of hundreds of thousands of compounds. Recently, scientists at Abbott Laboratories have successfully developed a new assay format for HTS, µArrayed Compound Screening (µARCS), which is a well-less screening technology. 11 This technology is licensed exclusively to Discovery Partners International (DPI, San Diego, CA). In this format, compounds are arrayed onto a polystyrene sheet, and the assay components are incorporated into thin agarose gels, which are layered one on top of the other, mimicking the pipetting steps in a plate assay. Based on the diffusion phenomenon, the compounds would move into the gels and the assay components would migrate from one gel to the other to carry out biological reactions. Therefore, the technology supplants the conventional solution-based assay format to search for potential lead inhibitors. We have performed both homogeneous enzymatic assays and multistep complex assays [12] [13] [14] in this format. µARCS not only increased the throughput of the screening process but also considerably reduced the amount and cost of the biological reagents used in the screening. 15 Here we describe the use of a streptavidin-coated membrane, the SAM 2® membrane, in the development of the µARCS format for 2 viral nucleic acid polymerization assays: 1) an HIV reverse transcription assay and 2) an E1 helicase-dependent human papillomavirus (HPV) replication assay, which uses cell-free extract as an enzyme source for DNA polymerization. The nucleic acid polymerization reaction in both studies occurs on the surface of the SAM 2® membrane. These assay procedures further expand the applications of µARCS technology to HTS.
MATERIALS AND METHODS

General reagents and materials
The SAM 2® biotin capture membrane, or the SAM 2® membrane, is a streptavidin-coated membrane that binds biotinylated molecules based on their affinity for streptavidin and was purchased from Promega (Madison, WI). Low melting-point (LMP) agarose was a product of Life Technology (Rockville, MD). α-33 P-TTP (800 Ci/mmol) and α-33 P-dCTP (3000 Ci/mmol) were purchased from PerkinElmer Life Sciences (Boston, MA). NTPs and dNTPs were the products of Roche Molecular Biochemicals (Indianapolis, IN). HIV reverse transcriptase assay buffer contained 50 mM Tris-HCl (pH 7.5), 50 mM KCl, 0.5 mM EDTA, and 4 mM βmercaptoethanol; 10 mM MgCl 2 was added to initiate the enzymatic reaction. HPV DNA replication assay buffer consisted of 30 mM HEPES (pH 7.5); 7.5 mM NaCl; 7 mM MgCl 2 ; 0.5 mM DTT; 0.5 mM β-mercaptoethanol; 200 µM each of GTP, UTP, and CTP; 4 mM ATP; 100 µM each of dGTP, dTTP, and dATP; 0.25 µM dCTP; 40 mM creatine phosphate; 2.5% glycerol; and 0.1 mg/mL creatine kinase. SAM 2® membrane-washing buffer contained 2N NaCl in 1× TE buffer (10 mM Tris, pH 7.5, 1 mM EDTA).
RNA and DNA template preparations
A 2.8-kb RNA was in vitro transcribed as follows: 50 µg of the plasmid DNA pGEM-13zf (Promega) was linearized with restriction enzyme Nae I, extracted with phenol, and purified using the Qiaquick (QIAGEN, Alameda, CA) spin purification protocol. The entire DNA was subsequently used to transcribe the 2.8-kb RNA using the Ambion MEGAscript transcription protocol. The resulting reaction mixture was then treated with DNase I and extracted with phenol prior to using the RNeasy Maxi kit (QIAGEN) to purify the RNA. The purified RNA was quantified and used at a final concentration of 1 µM in the annealing reaction. A 25-mer deoxyoligonucleotide primer, 5′-AAGCTCTAAATCGGGGGCTCCCTTT-3′, was synthesized and biotinylated at the 5′ end at Abbott Laboratories. The annealing reaction with the 2.8-kb RNA proceeded as follows: 1 µM RNA was mixed with 1 µM primer in an annealing buffer (100 mM Tris [pH 8.0], 10 mM EDTA, 500 mM NaCl), heated to 94°C for 5 min, 50°C for 30 min, and 25°C for 10 min. Aliquots of the annealed reactions were stored at -80°C until used.
The substrate for the HPV E1-dependent DNA replication assay was a 4.0-kb plasmid DNA, which was linearized and biotinylated as follows. Plasmid p51 was first linearized by digestion with Asp I (Fig. 1 ). End filling with biotin-dUTP (Roche Molecular Biochemicals, Laval, Quebec) was accomplished by incubating a mixture of 0.033 µg/mL linear p51 DNA, 20 µM ATP, 5 µM biotin-dUTP, and 0.017 U/mL in 1× Klenow buffer (50 mM Tris [pH 8.0], 10 mM MgCl 2 , 50 mM NaCl) for 30 min at room temperature. EDTA was added to a final concentration of 20 mM, and the reaction was passed over a G-50 spin column (Roche Molecular Biochemicals). The biotinylated DNA was precipitated in Na acetate/EtOH in the presence of 20 µg glycogen and resuspended in 1× TAE buffer (4 mM Tris-Acetate, 1 mM EDTA).
Enzyme preparations
The wild-type HIV reverse transcriptase (wtRT) was purchased from Wilmington Biochemical Corporation (Lakewood, NJ). The RT variant was constructed, expressed, and purified at Abbott Laboratories (data not shown).
HPV E1 helicase (strain 11, 78 kD) was expressed and purified as follows: High Five cells were cotransfected with a plasmid (UpAc-SG2) encoding E1, preceded by a FLAG epitope tag and a consensus phosphorylation sequence for protein kinase A (Arg Arg Ala Ser Val), as well as the BaculoGold baculovirus expression vector (Pharmingen, San Diego, CA). Recombinant virus was harvested from these cells and used to infect High Five cells. Harvested cells (11-13 × 10 8 cells) were centrifuged, and the cell pellet was resuspended in 5 volumes of B9 buffer (0.2 M Tris-HCl [pH 8.0], 40 mM MgCl 2 , 0.4% IGEPAL CA630, 4 mM EDTA, 40% glycerol, 1 mM DTT, 1 mM PMSF, and 1× protease inhibitor cocktail [Roche Molecular Biochemicals]) containing 0.2 M NaCl. The cells were then chilled in a bucket to -10°C by adding NaCl to the ice water in the bucket and lysed by sonication. The lysate was centrifuged at 100,000 g at 4°C for 30 min. The protein was concentrated by 35% ammonium sulfate precipitation, centrifuged at 20,000 g at 4°C for 10 min, and resuspended in 20 mL B9 by pipetting and rotating at 4°C for 30 min before dialyzing 2 times each for 2 hours or overnight against the B9 buffer containing 0.15 M NaCl. After dialysis, the protein suspension was centrifuged at 20,000 g for 10 min. The HPV E1 protein was further purified by affinity chromatography using an anti-FLAG monoclonal antibody derivatized to an agarose resin (M2, Eastman Kodak). E1 was bound to the resin in batches by incubation for 4 h to overnight (0. mL resin per 2 × 10 9 cells). Resin was washed with 20 volumes of B9 buffer containing 0.5 M potassium acetate. E1 was eluted in this buffer containing 600 µg/mL anti-FLAG peptide (Asp Tyr Lys Asp Asp Asp Asp Lys, Eastman Kodak). The purity and structural integrity of the E1 protein were determined by Coomasie blue staining on SDS-PAGE and by Western blot. The concentration of protein was determined by Bradford assay. HPV E2 protein was expressed and purified as follows: Escherichia coli BL21/DE3/pLysS, containing plasmid His-FLAG-PKA-E2 (a gift from Chiang and Roeder 16 ), was grown in Terrific broth containing 100 µg/mL ampicillin/34 µg/mL chloramphenicol for a cell density of 0.8 A 600 units/mL, and the E2 expression was induced with 1 mM IPTG at 30°C for another 3 h. The cells were harvested and resuspended in 25 mL of lysis buffer (250 mM Tris-HCl [pH 7.5], 5 mM EDTA, 0.5% Triton X-100, 50% glycerol, 1 mM DTT, 0.5 mM PMSF, 1× protease inhibitor cocktail, 0.15 M NaCl) containing 100 µL Benzonase from a 250-U/ mL stock. The cell suspension was sonicated 4 times each for 30 sec in ice water, incubated on a rotator at 4°C for 1 h, and centrifuged at 100,000 g for 30 min. E2 was purified from the supernatant by FLAG affinity chromatography, as described for E1.
Cell extract preparation
The preparation of cell extract for the E1-dependent HPV replication assay was based on the procedures described by Li and Kelly 17 and Stillman and Gluzman. 18 Briefly, HEK293 cells were grown to confluence, harvested by centrifugation at 500 to 1000 g for 3 to 5 min, and resuspended in PBS. The cells were repelleted 1 time in a cold isotonic buffer (0.1 M HEPES-K [pH 7.8], 25 mM KCl, 7.5 mM MgCl 2 , 1.25 M sucrose, 1 mM DTT, and 0.1 mM PMSF) and 2 times in a cold hypotonic buffer (0.1 M HEPES-K [pH 7.8], 25 mM KCl, 7.5 mM MgCl 2 , 1 mM DTT, and 0.1 mM PMSF). The first 2 spins were done at 4°C at 1600 rpm for 5 min, and the last spin was done for 15 min. The cell pellet was resuspended to a concentration of 10 8 cells/mL in hypotonic buffer. The cells were homogenized using a B pestle in a Dounce homogenizer for 5 strokes or until at least 90% of cells were lysed, as measured by Trypan blue exclusion. The lysate was kept on ice for 30 to 60 min, transferred to a cold centrifuge tube, and spun at 4°C at 33,000 g for 20 min. The supernatant was frozen drop wise in liquid nitrogen with a wide-bore pipet tip and stored at -70°C. The protein concentration was determined by Bradford assay. The cell extracts contain DNA polymerases, DNA primase, and singlestrand DNA binding proteins.
RESULTS
HIV reverse transcription assay
For the development of the µARCS format, we incorporated the assay reagents in an LMP agarose gel casted on a 14-cm × 24-cm standard BioRad protein gel apparatus (BioRad, Hercules, CA) with a 0.75-mm spacer. LMP agarose was first dissolved to 2% in ddH 2 O in a microwave and kept at 37°C in a water bath until further use. Substrates or enzyme solutions were then prepared at 2 times their final concentrations and prewarmed to 37°C in a water bath for 5 to 10 min and combined with the melted agarose to make 1× concentration in 1% agarose. The solution was quickly mixed by a pipettor several times in the water bath before pouring into the gel apparatus, which was also prewarmed to 37°C. The gel cassette was immediately chilled to 4°C in a refrigerator for 15 to 20 min until the agarose gel containing assay reagents was solidified.
Two non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz (extracted from Sustiva ® tablets from Bristol-Myers Squibb) and nevirapine (a generous gift from Boehringer-Ingelheim), were used to evaluate the HIV RT assay in the µARCS format. The compounds were dissolved in DMSO and diluted in 2fold dilution series from 2 mM to 150 nM. Then, 1 µL of each dilution was applied to a 0.5-mm polystyrene sheet and dried under vacuum for 30 min. As a proof of principle for the assay format, the biotinylated-primer/RNA substrate (25 nM) was first embedded in a 1% LMP agarose gel and transferred onto the SAM 2® membrane by Northern blot. 19, 20 The wtRT and the RT variant (25 nM of each enzyme) were integrated into another LMP agarose gel, along with 10 mM MgCl 2 , 10 µM each dNTPs, and 25 µCi/mL α-33 P-TTP. The enzyme gel was preincubated with the compound sheet for 15 min at room temperature before being placed on top of the SAM 2® membrane bound with the biotinylated-primer/RNA substrate to initiate the reaction. After the incubation at 37°C for 30 min, the SAM 2® membrane was washed 5 times with an excess amount of the membrane-washing buffer. The membrane was then air-dried and exposed for imaging using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The inhibition responses by efavirenz and nevirapine are shown in Figure 2 . The RT reactions appear as a dark background, whereas the inhibition patterns by the 2 inhibitors appear as white spots on the dark background. The inhibition sensitivity of efavirenz, the spot with the lowest concentration visible, by the wtRT is 63 fmol and by the RT variant is less than 0.6 pmol. The inhibition sensitivity of nevirapine by the wtRT is 1.25 pmol and by the RT variant is 1000 pmol. Simultaneously, we tested the IC 50 s of these inhibitors in a 96-well microplate format. The results in the µARCS format are consistent with the IC 50 s of the inhibitors to the corresponding RTs in the plate format (Table 1) , which indicate that the assay performance in the µARCS format is similar to the solution-based assay. These demonstrated that RNA polymerization did occur between the agarose gel and the membrane surface during the enzymatic reaction. This suggested that the µARCS format could be implemented for nucleic acid polymerization assays for HTS as with the 96-well plate format.
To further simplify the assay format and conserve the reagents, we applied a mixture of the biotin-primer/RNA substrate and the RT variant in the assay buffer in the absence of magnesium directly to a glass surface and laid a prewetted SAM 2® membrane on the surface containing the mixture, allowing 15 min for binding. A brief schematic representation of the assay procedure is shown in Figure 3 . This step allowed sufficient binding of the RT enzyme to its RNA substrate without initiation of the enzyme reaction, and it also eliminated the need to make a substrate gel. Only 1 agarose gel was made containing 10 mM magnesium, 1 µM each dNTPs, and 12.5 µCi/mL α-33 P-TTP in the assay buffer. This gel was placed on top of the polystyrene sheet containing dried test compounds for 15 min at room temperature for passive diffusion of the compounds into the gel. To initiate the enzymatic reaction, the agarose gel was then placed on top of the SAM 2® membrane containing immobilized biotin-primer/RNA substrate/RT enzyme and incubated at 37°C for 30 min. The SAM 2® membrane was then washed and exposed for imaging as in the previous experiment. The comparison of the image of the membrane from the experiment with 12.5 nM of each substrate and enzyme ( Fig. 4B ) with that of 25 nM of each substrate and enzyme (Fig. 4A ) showed that the inhibition response to efavirenz was similar for both concentrations of the enzyme/substrate tested, as the inhibition spots were developed up to a concentration of 0.15 pmol, the lowest concentration spotted in this experiment. The contrast of the spot at 0.15 pmol on the mem-brane with 25 nM of the reagents (Fig. 4A ) may have been masked by the lighter background of the image. To conserve the reagents, 12.5 nM of each substrate and enzyme was selected as an optimal concentration for further studies (Fig. 4B ). 
RT Variant wtRT
This format was used to screen a subset of the Abbott library compounds in duplicate using the RT variant. The compounds were dispensed as high-density arrays on polystyrene sheets (Tekra Corp., New Berlin, WI), which has the same footprint as a 96-well microplate. A total of 8640 compounds are arrayed 1 mm apart using 40 nl of a 5-mM stock compound solution to give 200pmol compound concentration per spot using a Pixsys nQuad dispenser (Cartesian Technologies, Irvine, CA). The normal and deconvoluted sheet format allows testing of each compound on 2 different sheets, and each compound is present on the sheets in 2 different locations. 6 The enzyme assay was performed as optimized above, and Figure 5 shows the images obtained in the PhosphorImager. Efavirenz was used as the constellation spots at an amount of 2.5 pmol per spot for orienting the image (dotted arrows) in the database for data analysis and hit picking and as a positive control. An internally developed database was used for image analysis and image storage. 11, 21 A dilution series of efavirenz was applied to the upper left edge of the first sheet, as indicated in the rectangular box in Figure 5 
Viral DNA replication assay
The µARCS format can also be extended to DNA polymerization using crude cell extracts. An E1-dependent HPV replication assay was formatted in the µARCS system, as shown in Figure 6 (protocol chart). A SAM 2® membrane was prewetted in ddH 2 O and evenly coated on 1 side for 5 to 10 min at room temperature with 10 mL of 4 µg/mL biotinylated linear plasmid DNA. The excess solution was removed from the membrane, which was kept wet in 1 × TE buffer until use. A 1% LMP agarose gel was prepared containing the following: 0.3 µg/mL E2, 3 µL/mL E1 (the specific activity was optimized for each preparation), 0.5 mL of crude cell extract per mL of agarose, and 15 µCi of α-33 P-dCTP per mL of agarose in DNA replication assay buffer. The gel was then preincubated with a polystyrene sheet containing dried test compounds for 15 min at room temperature. DNA polymerization was initiated when the agarose gel, containing crude cell extract and other DNA replication components, was placed in contact with the DNA-bound SAM 2® membrane. After incubation at 37°C for 3.5 h, the gel was removed. The membrane was then washed with the membrane-washing buffer and imaged using a PhosphorImager. The 33 P-labeled DNA on the membrane results in a dark image in the absence of inhibition. Areas where an inhibitor decreases the amount of DNA replication result in light spots.
In Figure 7 (DNA dose response), 2 known inhibitors of HPV replication, which were identified in a standard 96-well plate screen, were used to evaluate the effect of the DNA template concentration on the detection sensitivity in the µARCS format. As seen in the figure, with increasing concentration of the DNA template, the background became darker, giving better contrast with the inhibition spots and better sensitivity. A total of 4 µg per mL DNA was selected as an optimal concentration for further studies (membrane 2 of Fig. 7) . Several known HPV DNA replication inhibitors, also identified in 96-well screening, along with aphidicolin, a known mammalian DNA replication inhibitor, were used to evaluate the feasibility of the µARCS format for this multiple-component assay. As shown in Figure 8 , each compound appears to give a distinct inhibition dose response in spot intensity and size of diffusion. The inhibition spot sizes by aphidicolin appear to be larger than those by other inhibitors, whereas the inhibi-tion sizes by compound D appear to be the smallest. This diffusion pattern seems to be dependent on the molecular weight and the solubility of the compound. In general, the potency of each compound, when calculated as µARCS IC 50 s, is comparable to the IC 50 s generated in a 96-well plate format ( Table 2 ). The discrepancy in IC 50 s of compound A between µARCS and 96-well formats may be caused by the low aqueous solubility of the compound, and hence the diffusion pattern of the compound relative to the control compound as indicated above.
DISCUSSION
In summary, nucleic acid polymerization assays, such as 1) HIV reverse transcription, a homogeneous enzyme-based assay, and 2) E1-dependent HPV replication, a multiple-component assay with a crude cell extract, could be adapted into the µARCS format to screen libraries of synthetic compounds, using a SAM 2® membrane as a carrier for the nucleic acid template and subsequent polymerization reaction. The µARCS format allows the integration and flexible handling of various washing steps to remove unincorporated nucleotides and other nonspecific materials and further simplifies the assay procedure. To screen the same-size compound library, this format could potentially save half the amount of cell extract, plasmid DNA, and 33 P-nucleotide in comparison to a 96well plate format with 10 compounds per well for E1-dependent HPV replication assay. It could also potentially save up to 3 times the amount of enzyme and substrate reagents for the HIV RT assay, and it could shorten the screening time line by a factor of 5 for both assays. In 96-well format HTS operations, both assays would involve multiple steps of reagent additions and extensive washings, although the E1-dependent HPV replication assay would require even more reagents and reaction steps, which would often result in high cost, a poor signal-to-noise ratio, and a large amount of radioactive waste if isotopes were used. The sensitivity of the assay generally depends on the amount of substrate/enzyme reagents applied to the assay. It is pivotal, therefore, during assay development to optimize the assay reagents using the best control compound available as in the assay validation of the plate format, although it could be even more important for the success of the µARCS format, as shown in Figure 7 . The absolute quantitation of the potency of some compounds could be difficult in the µARCS format due to the solubility and diffusion characteristics of the compounds, as we observed in Figure 8 . However, as discussed in a recent publication on HIV DNA integrase screening in the µARCS format, 21 the intensity and size of the inhibition spots appear to correlate with the potency of the compound. Larger and darker spots, which were picked as highest quality spots of 3 qualities in the database, were produced by more potent compounds, and when IC 50 determination was performed in a 96-well solution format, these compounds generated lower IC 50 values. Experiments to understand the compound diffusion phenomenon in the agarose gel and the effect of the solubility of the compounds on the size of inhibition spots are currently being evaluated. No attempt has been made to completely automate the µARCS format yet. However, the DPI has developed a gel caster, which is easier to use than the BioRad apparatus because the gel casting has been the most labor-intensive part of the µARCS format. We are also evaluating the utilization of luminescence-or fluorescence-labeled nucleotides instead of radioactive ones to further advance the capability of this format for other nucleic acid polymerization assays. FIG. 6 . Protocol for E1-dependent human papillomavirus (HPV) replication in µARCS format. A SAM 2® membrane was prewetted in ddH 2 O and evenly coated with biotinylated linear plasmid DNA on one side. A 0.75-mm 1% low melting-point (LMP) agarose gel was prepared containing E1, E2, cell extract, NTPs, dNTPs, creatine kinase, and 33 P-dCTP and placed on top of a compound sheet for 15 min at room temperature. To initiate the reaction, the agarose gel was transferred to the membrane containing the biotinylated linear plasmid DNA and incubated at 37°C for 3.5 h. The membrane was then peeled from the gel, washed with the membrane-washing buffer, and used to expose a PhosphorImager screen. FIG. 7 . Effect of DNA template concentration on the detection sensitivity of the E1-dependent human papillomavirus (HPV) replication assay. Two compounds, A and C, were used in 100-pmol and 200-pmol amounts in each reaction. Membrane 1 was coated with 3 mL of 8 µg/mL DNA (30.4 pmol DNA); membrane 2 was coated with 3 mL of 4 µg/mL DNA (15.2 pmol DNA), which was later used as the optimal DNA concentration; membrane 3 was coated with 3 mL of 2 µg/mL DNA (7.6 pmol DNA); and membrane 4 was coated with 3 mL of 1 µg/mL DNA (3.8 pmol DNA). 
